Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?

Identifieur interne : 000122 ( Pmc/Curation ); précédent : 000121; suivant : 000123

Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?

Auteurs : Morvarid Karimi [États-Unis] ; Stephen M. Moerlein [États-Unis] ; Tom O. Videen [États-Unis] ; Robert R. Luedtke [États-Unis] ; Michelle Taylor [États-Unis] ; Robert H. Mach [États-Unis] ; Joel S. Perlmutter [États-Unis]

Source :

RBID : PMC:3025272

Abstract

Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular dysfunction of D2-like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography (PET) that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [18F]spiperone a non-selective D2-like radioligand with nearly equal affinity for serotonergic 5-HT(2A) sites. We then repeated the study with [18F]N-methyl-benperidol (NMB), a more selective D2-like receptor radioligand with minimal affinity for 5-HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. Following analysis of the in vitro selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200-fold difference in affinity), whereas spiperone has similar affinity for all three of the D2-like receptor subtypes. These findings coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia.


Url:
DOI: 10.1002/mds.23401
PubMed: 20960437
PubMed Central: 3025272

Links toward previous steps (curation, corpus...)


Links to Exploration step

PMC:3025272

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?</title>
<author>
<name sortKey="Karimi, Morvarid" sort="Karimi, Morvarid" uniqKey="Karimi M" first="Morvarid" last="Karimi">Morvarid Karimi</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Moerlein, Stephen M" sort="Moerlein, Stephen M" uniqKey="Moerlein S" first="Stephen M." last="Moerlein">Stephen M. Moerlein</name>
<affiliation wicri:level="1">
<nlm:aff id="A2">Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A5">Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Videen, Tom O" sort="Videen, Tom O" uniqKey="Videen T" first="Tom O." last="Videen">Tom O. Videen</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A2">Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Luedtke, Robert R" sort="Luedtke, Robert R" uniqKey="Luedtke R" first="Robert R." last="Luedtke">Robert R. Luedtke</name>
<affiliation wicri:level="1">
<nlm:aff id="A3">Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Taylor, Michelle" sort="Taylor, Michelle" uniqKey="Taylor M" first="Michelle" last="Taylor">Michelle Taylor</name>
<affiliation wicri:level="1">
<nlm:aff id="A3">Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Mach, Robert H" sort="Mach, Robert H" uniqKey="Mach R" first="Robert H." last="Mach">Robert H. Mach</name>
<affiliation wicri:level="1">
<nlm:aff id="A2">Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A4">Department of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A5">Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A2">Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A6">Department of Neurobiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurobiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A7">Department of Occupational Therapy, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Occupational Therapy, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A8">Department of Physical Therapy, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Physical Therapy, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">20960437</idno>
<idno type="pmc">3025272</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025272</idno>
<idno type="RBID">PMC:3025272</idno>
<idno type="doi">10.1002/mds.23401</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">000122</idno>
<idno type="wicri:Area/Pmc/Curation">000122</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?</title>
<author>
<name sortKey="Karimi, Morvarid" sort="Karimi, Morvarid" uniqKey="Karimi M" first="Morvarid" last="Karimi">Morvarid Karimi</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Moerlein, Stephen M" sort="Moerlein, Stephen M" uniqKey="Moerlein S" first="Stephen M." last="Moerlein">Stephen M. Moerlein</name>
<affiliation wicri:level="1">
<nlm:aff id="A2">Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A5">Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Videen, Tom O" sort="Videen, Tom O" uniqKey="Videen T" first="Tom O." last="Videen">Tom O. Videen</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A2">Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Luedtke, Robert R" sort="Luedtke, Robert R" uniqKey="Luedtke R" first="Robert R." last="Luedtke">Robert R. Luedtke</name>
<affiliation wicri:level="1">
<nlm:aff id="A3">Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Taylor, Michelle" sort="Taylor, Michelle" uniqKey="Taylor M" first="Michelle" last="Taylor">Michelle Taylor</name>
<affiliation wicri:level="1">
<nlm:aff id="A3">Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Mach, Robert H" sort="Mach, Robert H" uniqKey="Mach R" first="Robert H." last="Mach">Robert H. Mach</name>
<affiliation wicri:level="1">
<nlm:aff id="A2">Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A4">Department of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A5">Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation wicri:level="1">
<nlm:aff id="A1">Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A2">Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A6">Department of Neurobiology, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurobiology, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A7">Department of Occupational Therapy, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Occupational Therapy, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1">
<nlm:aff id="A8">Department of Physical Therapy, Washington University School of Medicine, Saint Louis, Missouri, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Physical Therapy, Washington University School of Medicine, Saint Louis, Missouri</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p id="P1">Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular dysfunction of D2-like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography (PET) that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [
<sup>18</sup>
F]spiperone a non-selective D2-like radioligand with nearly equal affinity for serotonergic 5-HT(2A) sites. We then repeated the study with [
<sup>18</sup>
F]N-methyl-benperidol (NMB), a more selective D2-like receptor radioligand with minimal affinity for 5-HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. Following analysis of the
<italic>in vitro</italic>
selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200-fold difference in affinity), whereas spiperone has similar affinity for all three of the D2-like receptor subtypes. These findings coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article" xml:lang="EN">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8610688</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5937</journal-id>
<journal-id journal-id-type="nlm-ta">Mov Disord</journal-id>
<journal-title>Movement disorders : official journal of the Movement Disorder Society</journal-title>
<issn pub-type="ppub">0885-3185</issn>
<issn pub-type="epub">1531-8257</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">20960437</article-id>
<article-id pub-id-type="pmc">3025272</article-id>
<article-id pub-id-type="doi">10.1002/mds.23401</article-id>
<article-id pub-id-type="manuscript">NIHMS225271</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Karimi</surname>
<given-names>Morvarid</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moerlein</surname>
<given-names>Stephen M.</given-names>
</name>
<degrees>Pharm D, PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Videen</surname>
<given-names>Tom O.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luedtke</surname>
<given-names>Robert R.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taylor</surname>
<given-names>Michelle</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mach</surname>
<given-names>Robert H.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perlmutter</surname>
<given-names>Joel S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>
Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA</aff>
<aff id="A2">
<label>2</label>
Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, Missouri, USA</aff>
<aff id="A3">
<label>3</label>
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas, USA</aff>
<aff id="A4">
<label>4</label>
Department of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, Missouri, USA</aff>
<aff id="A5">
<label>5</label>
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri, USA</aff>
<aff id="A6">
<label>6</label>
Department of Neurobiology, Washington University School of Medicine, Saint Louis, Missouri, USA</aff>
<aff id="A7">
<label>7</label>
Department of Occupational Therapy, Washington University School of Medicine, Saint Louis, Missouri, USA</aff>
<aff id="A8">
<label>8</label>
Department of Physical Therapy, Washington University School of Medicine, Saint Louis, Missouri, USA</aff>
<author-notes>
<corresp id="cor1">
<bold>Correspondence:</bold>
M. Karimi, 660 S. Euclid, Campus Box 8111, St. Louis, MO 63110-1093, Fax: (314) 362-0168, Telephone: (314) 362-6026,
<email>morvaridk@npg.wustl.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>8</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>10</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2011</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>1</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>1</issue>
<fpage>100</fpage>
<lpage>106</lpage>
<abstract>
<p id="P1">Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular dysfunction of D2-like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography (PET) that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [
<sup>18</sup>
F]spiperone a non-selective D2-like radioligand with nearly equal affinity for serotonergic 5-HT(2A) sites. We then repeated the study with [
<sup>18</sup>
F]N-methyl-benperidol (NMB), a more selective D2-like receptor radioligand with minimal affinity for 5-HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. Following analysis of the
<italic>in vitro</italic>
selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200-fold difference in affinity), whereas spiperone has similar affinity for all three of the D2-like receptor subtypes. These findings coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia.</p>
</abstract>
<kwd-group>
<kwd>dystonia</kwd>
<kwd>dopamine</kwd>
<kwd>NMB</kwd>
<kwd>D2-like dopamine receptors</kwd>
<kwd>D3 dopamine receptor</kwd>
<kwd>PET</kwd>
</kwd-group>
<contract-num rid="NS1">R01 NS058714-03 ||NS</contract-num>
<contract-num rid="NS1">R01 NS050425-05 ||NS</contract-num>
<contract-num rid="NS1">R01 NS041509-09 ||NS</contract-num>
<contract-num rid="NS1">R01 NS031001-06 ||NS</contract-num>
<contract-sponsor id="NS1">National Institute of Neurological Disorders and Stroke : NINDS</contract-sponsor>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000122 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000122 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Pmc
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:3025272
   |texte=   Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i   -Sk "pubmed:20960437" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024